398 related articles for article (PubMed ID: 12915604)
1. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer.
Yang JC; Sherry RM; Steinberg SM; Topalian SL; Schwartzentruber DJ; Hwu P; Seipp CA; Rogers-Freezer L; Morton KE; White DE; Liewehr DJ; Merino MJ; Rosenberg SA
J Clin Oncol; 2003 Aug; 21(16):3127-32. PubMed ID: 12915604
[TBL] [Abstract][Full Text] [Related]
2. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma.
McDermott DF; Regan MM; Clark JI; Flaherty LE; Weiss GR; Logan TF; Kirkwood JM; Gordon MS; Sosman JA; Ernstoff MS; Tretter CP; Urba WJ; Smith JW; Margolin KA; Mier JW; Gollob JA; Dutcher JP; Atkins MB
J Clin Oncol; 2005 Jan; 23(1):133-41. PubMed ID: 15625368
[TBL] [Abstract][Full Text] [Related]
3. An ongoing prospective randomized comparison of interleukin-2 regimens for the treatment of metastatic renal cell cancer.
Yang JC; Rosenberg SA
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S79-84. PubMed ID: 9457400
[TBL] [Abstract][Full Text] [Related]
4. The use of polyethylene glycol-modified interleukin-2 (PEG-IL-2) in the treatment of patients with metastatic renal cell carcinoma and melanoma. A phase I study and a randomized prospective study comparing IL-2 alone versus IL-2 combined with PEG-IL-2.
Yang JC; Topalian SL; Schwartzentruber DJ; Parkinson DR; Marincola FM; Weber JS; Seipp CA; White DE; Rosenberg SA
Cancer; 1995 Aug; 76(4):687-94. PubMed ID: 8625167
[TBL] [Abstract][Full Text] [Related]
5. Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report.
Yang JC; Topalian SL; Parkinson D; Schwartzentruber DJ; Weber JS; Ettinghausen SE; White DE; Steinberg SM; Cole DJ; Kim HI
J Clin Oncol; 1994 Aug; 12(8):1572-6. PubMed ID: 8040669
[TBL] [Abstract][Full Text] [Related]
6. Radiotherapy as an immunological booster in patients with metastatic melanoma or renal cell carcinoma treated with high-dose Interleukin-2: evaluation of biomarkers of immunologic and therapeutic response.
Ridolfi L; de Rosa F; Ridolfi R; Gentili G; Valmorri L; Scarpi E; Parisi E; Romeo A; Guidoboni M
J Transl Med; 2014 Sep; 12():262. PubMed ID: 25245327
[TBL] [Abstract][Full Text] [Related]
7. Subcutaneous interleukin-2 and interferon alfa administration in patients with metastatic renal cell carcinoma: final results of SCAPP III, a large, multicenter, phase II, nonrandomized study with sequential analysis design--the Subcutaneous Administration Propeukin Program Cooperative Group.
Tourani JM; Pfister C; Tubiana N; Ouldkaci M; Prevot G; Lucas V; Oudard S; Malet M; Cottu P; Ferrero JM; Mayeur D; Rixe O; Sun XS; Bernard O; Andre T; Tournigand C; Muracciole X; Guilhot J;
J Clin Oncol; 2003 Nov; 21(21):3987-94. PubMed ID: 14581421
[TBL] [Abstract][Full Text] [Related]
8. A phase 2 study of moderate dose interleukin-2 and granulocyte-macrophage colony-stimulating factor in patients with metastatic or unresectable renal cell carcinoma.
Koulova L; Novik Y; Caliendo G; Wiernik P; Dutcher J
J Immunother; 2005; 28(6):576-81. PubMed ID: 16224275
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial.
Clark JI; Atkins MB; Urba WJ; Creech S; Figlin RA; Dutcher JP; Flaherty L; Sosman JA; Logan TF; White R; Weiss GR; Redman BG; Tretter CP; McDermott D; Smith JW; Gordon MS; Margolin KA
J Clin Oncol; 2003 Aug; 21(16):3133-40. PubMed ID: 12810695
[TBL] [Abstract][Full Text] [Related]
10. Subcutaneous interleukin-2 and interferon alpha in the treatment of patients with metastatic renal cell carcinoma-Less efficacy compared with intravenous interleukin-2 and interferon alpha. Results of a multicenter Phase II trial from the Groupe Français d'Immunothérapie.
Ravaud A; Delva R; Gomez F; Chevreau C; Douillard JY; Peny J; Coudert B; Négrier S;
Cancer; 2002 Dec; 95(11):2324-30. PubMed ID: 12436438
[TBL] [Abstract][Full Text] [Related]
11. A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma.
Weiss GR; Margolin KA; Aronson FR; Sznol M; Atkins MB; Dutcher JP; Gaynor ER; Boldt DH; Doroshow JH; Bar MH
J Clin Oncol; 1992 Feb; 10(2):275-81. PubMed ID: 1732429
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant subcutaneous interleukin-2 in patients with resected renal cell carcinoma: a pilot study.
Majhail NS; Wood L; Elson P; Finke J; Olencki T; Bukowski RM
Clin Genitourin Cancer; 2006 Jun; 5(1):50-6. PubMed ID: 16859579
[TBL] [Abstract][Full Text] [Related]
13. Radiotherapy and High-Dose Interleukin-2: Clinical and Immunological Results of a Proof of Principle Study in Metastatic Melanoma and Renal Cell Carcinoma.
Bulgarelli J; Piccinini C; Petracci E; Pancisi E; Granato AM; de Rosa F; Guidoboni M; Petrini M; Ancarani V; Foschi G; Romeo A; Tontini L; De Giorgi U; Lolli C; Gentili G; Valmorri L; Rossi A; Ferroni F; Casadei C; Cortesi P; Crudi L; Ridolfi L
Front Immunol; 2021; 12():778459. PubMed ID: 34777395
[TBL] [Abstract][Full Text] [Related]
14. Five-year survival results of subcutaneous low-dose immunotherapy with interleukin-2 alone in metastatic renal cell cancer patients.
Bordin V; Giani L; Meregalli S; Bukovec R; Vaghi MM; Mandalà M; Paolorossi F; Ardizzoia A; Tancini G; Barni S; Frigerio F; Fumagalli L; Bordoni A; Valsuani G; Di Felice G; Lissoni P
Urol Int; 2000; 64(1):3-8. PubMed ID: 10782024
[TBL] [Abstract][Full Text] [Related]
15. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response.
Rosenberg SA; Yang JC; White DE; Steinberg SM
Ann Surg; 1998 Sep; 228(3):307-19. PubMed ID: 9742914
[TBL] [Abstract][Full Text] [Related]
16. Current status of interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma.
Dutcher JP
Oncology (Williston Park); 2002 Nov; 16(11 Suppl 13):4-10. PubMed ID: 12469934
[TBL] [Abstract][Full Text] [Related]
17. Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIM
Fishman M; Dutcher JP; Clark JI; Alva A; Miletello GP; Curti B; Agarwal N; Hauke R; Mahoney KM; Moon H; Treisman J; Tykodi SS; Daniels G; Morse MA; Wong MKK; Kaufman H; Gregory N; McDermott DF
J Immunother Cancer; 2019 Mar; 7(1):84. PubMed ID: 30917871
[TBL] [Abstract][Full Text] [Related]
18. Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIM
Clark JI; Wong MKK; Kaufman HL; Daniels GA; Morse MA; McDermott DF; Agarwala SS; Lewis LD; Stewart JH; Vaishampayan U; Curti B; Gonzalez R; Lutzky J; Rudraptna V; Cranmer LD; Jeter JM; Hauke RJ; Miletello G; Milhem MM; Amin A; Richart JM; Fishman M; Hallmeyer S; Patel SP; Van Veldhuizen P; Agarwal N; Taback B; Treisman JS; Ernstoff MS; Perritt JC; Hua H; Rao TB; Dutcher JP; Aung S
Clin Genitourin Cancer; 2017 Feb; 15(1):31-41.e4. PubMed ID: 27916626
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-2, interferon-alpha and interleukin-2 plus interferon-alpha in renal cell carcinoma. A randomized phase II trial.
Boccardo F; Rubagotti A; Canobbio L; Galligioni E; Sorio R; Lucenti A; Cognetti F; Ruggeri E; Landonio G; Baiocchi C; Besana C; Citterio G; De Rosa M; Calabresi F
Tumori; 1998; 84(5):534-9. PubMed ID: 9862512
[TBL] [Abstract][Full Text] [Related]
20. Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma.
Atkins MB; Sparano J; Fisher RI; Weiss GR; Margolin KA; Fink KI; Rubinstein L; Louie A; Mier JW; Gucalp R
J Clin Oncol; 1993 Apr; 11(4):661-70. PubMed ID: 8478661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
